ABI claimed that by taking Maxisal, cancer patients may be able to relieve at least one of the side effects of cancer therapy, dry mouth. Maxisal was first offered for sale after clinical studies in subjects with Sjogren’s syndrome reported that the ingredient in Maxisal improved mouth comfort and decreased mouth and throat dryness.
Joseph Cummins, president and CEO of ABI, said: “Based on the favorable reception Maxisal has met in the US we fully expect that it will be successful in Germany.”
ABI stated that it has prepared a dietary ingredient for natural food distributors to market as a dietary supplement. The ingredient is derived from animals in the feed yards of the Texas Panhandle.
Mr Cummins added: “We have developed a new dietary ingredient derived from ruminant animals. We are seeking distributors of dietary supplements and have initiated discussions in the USA, China, and South America.
“The animal product is expected to be available in June and revenues from both of the dietary supplements are expected to help the company fund its FDA clinical trials of oral human interferon in influenza and hepatitis C.”